Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough

Executive Summary

Submits comments to FDA on an acetaminophen/pseudoephedrine/chlorpheniramine ANDA suitability petition filed by the Washington, D.C. law firm Kleinfeld, Kaplan and Becker. Schering maintains that the petition should be denied because the proposed formulation is "considerably different" than that of the reference product Drixoral Plus. The antihistamine in Drixoral Plus is dexbropheniramine maleate 3 mg, whereas the antihistamine in the proposed product is chlorpheniramine maleate 6 mg, Schering said. The firm contends that the petitioner's drug is "a new drug," since there is no listed product to which the proposed product, particularly the chlorpheniramine component, can be compared....

You may also be interested in...



J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.

UsernamePublicRestriction

Register

PS014665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel